Continuous Glucose Monitoring Market Size & Share 2026-2035

Continuous Glucose Monitoring Market Size

The continuous glucose monitoring market size was valued at USD 12.4 billion in 2025 and is expected to reach USD 55.5 billion in 2035, growing at a CAGR of 16.3% from 2026 to 2035, according to the latest report published by Global Market Insights Inc.

The steady growth is driven by various factors, such as the rising prevalence of diabetes globally, the growing demand for continuous monitoring devices, technological advancements in devices, and increasing government initiatives to raise awareness about diabetes.

The rising global prevalence of diabetes is the primary factor driving market expansion. For example, a 2022 World Health Organization (WHO) report highlighted that around 830 million people worldwide were diabetic, predominantly from low and middle-income nations. Moreover, diabetes was responsible for 1.6 million deaths in 2021, with nearly half occurring before the age of 70. These alarming statistics underscore the urgent need for solutions like continuous glucose monitoring devices, which empower individuals to manage their health and address the global diabetes crisis.

Government initiatives aimed at raising diabetes awareness significantly influence the continuous glucose monitoring market. These efforts not only highlight the importance of diabetes monitoring but also improve access to monitoring devices. For instance, in the U.S., the Centers for Disease Control and Prevention (CDC) has implemented multiple programs targeting diabetes. One notable initiative is the National Diabetes Prevention Program, designed to prevent or delay the onset of type 2 diabetes. Through this program, the CDC provides valuable resources and insights into diabetes management tools, including CGM devices. Consequently, as CGM technology evolves and the global demand for monitoring devices surges, the push for more effective and specialized CGM solutions intensifies.

Continuous glucose monitoring (CGM) is a cutting-edge medical technology that tracks the body's glucose levels around the clock. Unlike traditional methods that rely on fingerstick blood samples, CGM systems use a tiny sensor placed beneath the skin, providing real-time measurements of interstitial glucose levels.

Continuous Glucose Monitoring Market Trends

• Continuous glucose monitoring (CGM) devices have evolved significantly with notable technological advancements in recent years, driving the growth of the market. These innovations in CGM have improved the accuracy, convenience, and user experience of CGM devices, making them more appealing to both patients and healthcare providers.
• The improvement in sensor accuracy and longevity represents a major technological advancement in CGM devices. Modern sensors now offer extended wear times and enhanced stability. For instance, the Stelo Glucose Biosensor by Dexcom provides a 15-day wear time along with a 12-hour grace period.
• Additionally, the incorporation of smart devices and data-sharing capabilities has enhanced the functionality of CGM devices. Many modern CGM devices transmit real-time glucose level data directly to smartphones, smartwatches, and other connected devices. This feature makes it more convenient for users to monitor and track their glucose levels while also enabling direct data sharing with healthcare providers.
• For example, the Freestyle Libre 2 system offers optional real-time alarms on smartphones, alerting users about their glucose levels.
• Furthermore, artificial intelligence in healthcare and machine learning are being integrated into CGM systems, offering personalized insights and analytical capabilities. These technologically advanced analytics help individuals and healthcare professionals identify patterns, predict future glucose levels and trends, and make informed decisions, thus contributing to the market growth.

Continuous Glucose Monitoring Market Analysis

Based on the component, the continuous glucose monitoring market is segmented into transmitters, sensors, and receivers. The sensors monitoring devices segment held revenues of USD 6.3 billion in the year 2025.

• Continuous advancements in sensor technology, particularly in terms of accuracy and reliability, are significantly driving the growth of the continuous glucose monitoring (CGM) market.
• Modern sensors have greatly improved their accuracy, with some devices achieving a mean absolute relative difference (MARD) of less than 10%. For example, a study published by the National Institutes of Health (NIH) in 2023 reported that Dexcom has an 8.2% MARD, while Abbott’s Freestyle Libre has a 9.7% MARD. This level of accuracy has led to increased adoption of CGM systems among individuals.
• Additionally, smaller sensors have made CGM devices more comfortable for users. For instance, the latest innovation in CGM sensors, the Dexcom G7, is approximately the size of a penny and can be worn discreetly under an individual’s clothing. This compact size has enhanced user comfort and allows the sensors to last up to 10 days of continuous use before requiring replacement.
• Furthermore, many new advanced biosensors, which are estimated to reach USD 68.5 billion by 2034, can monitor more than just glucose. These advanced sensors can also measure ketones or lactate levels in an individual’s body. This capability provides a more comprehensive picture of metabolic health and helps users manage their diabetes more effectively. As a result, this advancement is accelerating market growth.

Based on end use, the continuous glucose monitoring market is bifurcated into hospitals, home care settings, diagnostic centres and clinics, and other end users. The home care settings segment accounted for USD 10.1 billion in 2025.

• Homecare settings are increasingly adopting continuous glucose monitoring (CGM) systems to enable real-time glucose tracking, proactive glycemic control, and early detection of hypo- or hyperglycemic events outside clinical environments. CGM devices allow patients with diabetes to continuously monitor glucose trends at home, reducing emergency interventions and reliance on in-person hospital visits.
• The shift toward home-based and decentralized diabetes care models is accelerating demand for CGM solutions, particularly for long-term diabetes management, post-hospital discharge glucose stabilization, and elderly patient care.
• Advancements in CGM usability, wireless connectivity, and integrated digital platforms have strengthened adoption in homecare environments. User-friendly sensors, smartphone integration, cloud-based data sharing, automated alerts, and telehealth compatibility empower patients and caregivers to manage glucose levels confidently at home while enabling clinicians to remotely monitor trends, adjust therapy, and intervene promptly when required.

North America Continuous Glucose Monitoring Market

The North America region accounted for 47.3% of the market in 2025. The market in North America is experiencing robust expansion, driven by the region’s advanced healthcare infrastructure and technological advancements.

The U.S. market size reached USD 5.7 billion in 2025, growing from USD 4.9 billion in 2024.

• The growth of the continuous glucose monitoring market in the U.S. is strongly supported by high healthcare spending capacity and widespread access to advanced medical technology.
• The rising incidence of diabetes significantly contributes to the market's notable expansion. For instance, according to the 2023 National Diabetes Statistics Report by the Centers for Disease Control and Prevention (CDC), more than 40 million Americans, approximately 12% of the population, are living with diabetes, including over 2 million individuals with type 1 diabetes.
• The market has also expanded due to favorable reimbursement policies. Medicare has made its coverage for CGM devices more inclusive, increasing system accessibility to a wider population. Starting in January 2023, the Centers for Medicare & Medicaid Services (CMS) broadened the scope of CGM device coverage to include people with diabetes who take insulin or have experienced problematic hypoglycemia in the past.

Europe Continuous Glucose Monitoring Market

The Europe market accounted for USD 3 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• The rising prevalence of chronic diseases in the region, coupled with increasing government initiatives to enhance healthcare infrastructure, is anticipated to spur the growth of the market.
• Moreover, technological advancements in CGM devices, including minimally invasive wearable sensors, real-time glucose monitoring systems, and smartphone-integrated platforms, are significantly boosting market growth in Europe.
• The presence of key market players in the region reinforces Europe’s strength in the market. These companies are actively participating in innovation through the development of innovative solutions, thereby aiding market growth.

The market in the Germany is expected to experience significant and promising growth from 2026 to 2035.

• The growth of the continuous glucose monitoring market in this country is anticipated to be bolstered by the rising cases of diabetes in Germany.
• For instance, according to the International Diabetes Federation (IDF) estimates, 6,199,900 people in Germany were living with diabetes in 2021. Additionally, nearly 10% of the adult population had a prevalence of diabetes.
• Further, the growth of the market in this region is anticipated to be strengthened by the German government’s commitment to tackling chronic conditions via initiatives such as public health campaigns and guidelines promoting a healthier lifestyle, which is contributing to market growth.

Asia Pacific Continuous Glucose Monitoring Market

The Asia-Pacific region is projected to show lucrative growth of about 16.9% during the forecast period.

• The market in the Asia Pacific region is growing rapidly due to the increasing burden of chronic diseases, rising health awareness, and ongoing advancements in continuous glucose monitoring technology.
• Countries such as China, India, and Japan are adopting continuous glucose monitoring technology, driven by the rising demand for advanced diagnostic solutions and expanding access to healthcare services.
• Additionally, the rapid increase in the number of hospitals and diagnostic centers, along with government policies aimed at improving diagnostic capabilities, is further contributing to the market's growth in the region.

The China market is anticipated to witness lucrative growth during the forecast period.

• The country has one of the fastest-aging populations, which creates a need for frequent health monitoring.
• For instance, according to estimates from the World Health Organization in 2019, approximately 254 million people aged 65 and above were residing in the country. This number is projected to rise significantly, with 402 million people expected to be over the age of 60 by 2040.
• Individuals in this age group are at a high risk of developing chronic health conditions. This, in turn, drives the demand for medical devices such as continuous glucose monitoring systems, thereby propelling market growth in the region.

Latin America Continuous Glucose Monitoring Market

• The rising prevalence of diabetes and other metabolic disorders in Brazil, driven by lifestyle changes, urbanization, and an aging population, is significantly contributing to the growth of the market. The increasing burden of type 1 and type 2 diabetes is accelerating the demand for real-time glucose monitoring solutions to support long-term disease management and reduce diabetes-related complications.
• Growing awareness of the importance of early glucose imbalance detection and preventive diabetes care in Brazil, supported by public health programs, educational campaigns, and initiatives from healthcare organizations, is encouraging wider adoption of CGM devices.

Middle East and Africa Continuous Glucose Monitoring Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2026 to 2035.

• The Government of Saudi Arabia is making substantial investments in healthcare modernization under Vision 2030, promoting the adoption of advanced digital health technologies, including continuous glucose monitoring systems, across hospitals and outpatient care settings. These investments aim to enhance diabetes management, improve patient outcomes, and reduce long-term complications associated with poor glycemic control.
• According to the Saudi Ministry of Health, in 2023, the government allocated approximately USD 50.4 billion for healthcare infrastructure and social development.
• Moreover, rising awareness of diabetes self-management, preventive healthcare, and the benefits of continuous glucose monitoring across various age groups in Saudi Arabia is further driving market growth.

Continuous Glucose Monitoring Market Share

• The top five players in the continuous glucose monitoring industry, namely Abbott Laboratories, Ascensia Diabetes Care Holdings, F. Hoffmann-La Roche, Medtronic, and Dexcom, collectively hold a 99% share of the global market. These companies maintain their leadership through diverse product portfolios, strategic collaborations, regulatory approvals, and ongoing innovation. Abbott Laboratories stands out due to its comprehensive range of CGM devices, which are widely adopted in hospitals and diagnostic centers.
• Abbott Laboratories stands out with its FreeStyle Libre platform, which has gained widespread adoption across multiple regions due to its ease of use, affordability, and advanced data connectivity. Abbott continues to enhance its CGM offerings by integrating real-time glucose monitoring with cloud-based analytics and mobile health applications, supporting personalized and proactive diabetes management.
• Manufacturers are embracing value-based pricing models to improve accessibility in diverse healthcare systems while also launching AI-enabled CGM platforms that feature predictive glucose alerts, automated data interpretation, and seamless integration with electronic health records.
• Key trends shaping the market include the development of minimally invasive sensors, AI-powered decision support tools, and interoperable platforms designed for both clinical and home settings. Technologies such as continuous interstitial glucose monitoring, smartphone-based data visualization are significantly improving diagnostic accuracy, patient engagement, and long-term health outcomes worldwide.

Continuous Glucose Monitoring Market Companies

Some of the eminent market participants operating in the continuous glucose monitoring industry include:

• Abbott Laboratories
• A. Menarini Diagnostics
• Dexcom
• i-SENS
• F. Hoffmann-La Roche
• Med Trust
• Medtronic
• Medtrum Technologies
• Senseonics
• Sinocare
• Zhejiang POCTech
• Abbott Laboratories

Abbott Laboratories has a robust product portfolio that drives widespread adoption and significant market expansion. The company offers a diverse range of continuous glucose monitoring (CGM) products, including the FreeStyle Libre 2 and FreeStyle Libre 3, which are widely recognized for their innovation and accessibility.

• Dexcom

Dexcom is committed to research and development, continuously advancing its CGM technology. Its focus on innovation has led to the development of cutting-edge products such as the Dexcom G6 CGM System and the Dexcom G6 Pro CGM System, enhancing user experience and clinical outcomes.

• Medtronic

          Medtronic leverages its extensive global presence to strengthen market reach, operating in over 150 countries with a robust distribution network. Its CGM product portfolio includes standalone CGM systems as well as integrated solutions, such as CGM devices paired with automated insulin pump systems, offering comprehensive diabetes management.

Continuous Glucose Monitoring Industry News

• In September 2024, Abbott introduced its latest wearable, Lingo, a continuous glucose monitor, aimed at health-conscious individuals by helping them track their glucose levels without needing prior medical approval. This launch will expand the company’s product portfolio of continuous glucose monitors and may enable them to increase customer base.
• In March 2024, Dexcom received FDA clearance for its Stelo glucose biosensor, marking it as the first over-the-counter (OTC) continuous glucose monitor (CGM) available in the U.S. This move may position Dexcom as a leader in the CGM market, responding to increasing demand for accessible diabetes management tools.

The continuous glucose monitoring market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Transmitters
• Sensors
• Receivers

Market, By End Use

• Hospitals
• Home care settings
• Diagnostic centres and clinics
• Other end users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE